ArticleAging2019
A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of Metformin Use on Survival and Recurrence Rate of Gastric Cancer After Gastrectomy in Diabetic Patients: A Systematic Review and Meta-analysis of Observational Studies.Journal of gastrointestinal cancer · 2024 · on this mapPooled it
- The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020 · on this mapPooled it
- A sweet danger: the silent link between hyperinsulinemia and gastric cancer.Molecular cancer · 2026Review
- Risk Factors and Prevention of Stomach Cancer, ExcludingThe Korean journal of helicobacter and upper gastrointestinal research · 2024Review
- Review
- Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.Journal of diabetes research · 2023Review
- Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk.International journal of molecular sciences · 2022Review
- Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study.BMC gastroenterology · 2022Article
- The clinical features, management, and survival of elderly patients with gastric cancer.Journal of gastrointestinal oncology · 2022Article
- Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway.Cancer cell international · 2021Article
- The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature.Biomolecules · 2021Review
- Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.Scientific reports · 2021Article
- The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.Oncology letters · 2020Article
- Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival.International journal of environmental research and public health · 2020Article
- Review
- A Cohort Study of Antihyperglycemic Medication Exposure and Gastric Cancer Risk.Journal of clinical medicine · 2020Article
- Cancer of the Liver and its Relationship with Diabetes mellitus.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to estimate survival in gastric cancer patients with type 2 diabetes mellitus (T2DM) using different antihyperglycemic medication.
methodsPatients with gastric cancer and diabetes between 2003-2013 were identified form The Lithuanian Cancer Registry and The National Health Insurance Fund database. Cohort members were classified into five groups: four groups of T2DM patients according to treatment: metformin users; metformin and other medication users; sulphonylurea users; insulin and other medication users; and non-diabetic group. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate gastric cancer-specific survival and overall survival.
results8423 patients met eligibility criteria. Survival analysis showed no differences in gastric cancer-specific survival between non-diabetic and diabetic patient groups. Better survival was observed in the groups of patients using antihyperglycemic medication combinations with metformin, metformin alone or insulin. Lowest survival was observed in diabetic patients who were sulphonylurea users. Survival analysis comparing overall survival between non-diabetic and diabetic patients (p = 0.89) showed no evidence of survival difference between groups and survival differences between antihyperglycemic medication user groups were of borderline significance (p = 0.052).
conclusionsAntihyperglycemic medication use was not associated with a significant effect on survival in patients with gastric cancer and T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.